Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03035279 · ClinicalTrials.gov registry record · Phase 1
A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer
A Phase 1 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT03035279 is a Phase 1 study that was terminated before completion, run by AbbVie. The registered enrollment target is 29 participants.
The verdict
NCT03035279, a Phase 1 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, Phase 1 study of SC-006 given as a single agent and in combination with ABBV-181 in participants with advanced colorectal cancer (CRC), and consists of Part A (single agent SC-006 dose regimen finding), followed by Part B (single agent SC-006 dose expansion), and Part C (SC-006 and ABBV-181 combination escalation and expansion). Part A (dose regimen finding) will involve dose escalation and possible dose interval modification to define the maximum tolerated dose (MTD) and/or recommended Part B dose and schedule. Part B (dose expansion) will enroll additional participants who will be treated with a study drug dose at or below the MTD determined in Part A. Part C is dose escalation of SC-006 and fixed dose of ABBV-181 in combination. Recommended dose cohort of SC-006 with ABBV-181 will be expanded.
Interventions
- DRUG ABBV-181
- DRUG SC-006
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2017-03-08 |
| Est. Completion | 2019-03-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03035279
The ClinicalTrials.gov registry entry for NCT03035279 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ABBV-181 is the first listed.
NCT03035279 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03035279 about?
NCT03035279 is a clinical study titled "A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer". This is a multicenter, open-label, Phase 1 study of SC-006 given as a single agent and in combination with ABBV-181 in participants with advanced colorectal cancer (CRC), and consists of Part A (single agent SC-006 dose regimen finding), followed by Part B (single agent SC-006 dose expansion), and P...
What is the current status of trial NCT03035279?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2017-03-08. Estimated completion is 2019-03-28.
What interventions are being tested in trial NCT03035279?
The interventions under investigation include: ABBV-181 (DRUG), SC-006 (DRUG).
Who is sponsoring clinical trial NCT03035279?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.